Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 4599523)

Published in J Am Heart Assoc on June 18, 2015


Kenneth W Mahaffey1, Rebecca Hager2, Daniel Wojdyla2, Harvey D White3, Paul W Armstrong4, John H Alexander2, Pierluigi Tricoci2, Renato D Lopes2, E Magnus Ohman2, Matthew T Roe2, Robert A Harrington1, Lars Wallentin5

Author Affiliations

1: Department of Medicine, Stanford University, Stanford, CA (K.W.M., R.A.H.).
2: Duke Clinical Research Institute, Durham, NC (R.H., D.W., J.H.A., P.T., R.D.L., M.O., M.T.R.).
3: Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
4: Division of Cardiology, University of Alberta, Edmonton, Canada (P.W.A.).
5: Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (L.W.).

Associated clinical trials:

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (PLATO) | NCT00391872

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS) | NCT00699998

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736) | NCT00527943

Phase III Acute Coronary Syndrome (APPRAISE-2) | NCT00831441

Articles cited by this

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med (1998) 5.41

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49

Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10

Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke (2003) 3.56

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA (2004) 2.89

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J (2009) 2.23

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J (2009) 1.16

The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry (2011) 1.10

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J (2010) 1.07

Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. Circulation (1998) 0.98

Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. JACC Cardiovasc Interv (2013) 0.85

Articles by these authors

Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. J Am Heart Assoc (2014) 0.77